Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers

[1]  Mingyang Song,et al.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis , 2015, Gut.

[2]  C. Huttenhower,et al.  Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. , 2015, JAMA oncology.

[3]  S. Jonjić,et al.  Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. , 2015, Immunity.

[4]  K. Kinzler,et al.  Microbiota organization is a distinct feature of proximal colorectal cancers , 2014, Proceedings of the National Academy of Sciences.

[5]  F. Qiu,et al.  γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. , 2014, Immunity.

[6]  C. Benoist,et al.  Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. , 2014, Immunity.

[7]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy. , 2014, Current opinion in immunology.

[8]  Taeko Dohi,et al.  Dysbiosis of Salivary Microbiota in Inflammatory Bowel Disease and Its Association With Oral Immunological Biomarkers , 2013, DNA research : an international journal for rapid publication of reports on genes and genomes.

[9]  B. Becher,et al.  Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection , 2013, The Journal of experimental medicine.

[10]  J. Karbach,et al.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.

[11]  M. Meyerson,et al.  Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. , 2013, Cell host & microbe.

[12]  M. R. Rubinstein,et al.  Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. , 2013, Cell host & microbe.

[13]  M. Hattori,et al.  Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota , 2013, Nature.

[14]  Hiromasa Morikawa,et al.  Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression , 2013, Proceedings of the National Academy of Sciences.

[15]  M. Hattori,et al.  Robustness of Gut Microbiota of Healthy Adults in Response to Probiotic Intervention Revealed by High-Throughput Pyrosequencing , 2013, DNA research : an international journal for rapid publication of reports on genes and genomes.

[16]  D. Scholtens,et al.  Expression of RORγt Marks a Pathogenic Regulatory T Cell Subset in Human Colon Cancer , 2012, Science Translational Medicine.

[17]  K. Nakai,et al.  T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. , 2012, Immunity.

[18]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[19]  A. DeMichele,et al.  CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients , 2012, Science Translational Medicine.

[20]  R. deLeeuw,et al.  The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature , 2012, Clinical Cancer Research.

[21]  A. Rudensky,et al.  Regulatory T cells: mechanisms of differentiation and function. , 2012, Annual review of immunology.

[22]  R. deLeeuw,et al.  The prognostic value of FoxP 3 + tumor-infiltrating lymphocytes in cancer : 1 A critical review of the literature 2 3 4 * † , 2012 .

[23]  Janice K Popp,et al.  MMBA 8109: Research Methods Critical Review of Literature , 2012 .

[24]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[25]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[26]  D. Hafler,et al.  FOXP3+ regulatory T cells in the human immune system , 2010, Nature Reviews Immunology.

[27]  L. Terracciano,et al.  High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients , 2010, International journal of cancer.

[28]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Sargent,et al.  Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. , 2009, Gastroenterology.

[30]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[31]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[33]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[34]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[36]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.